Biggest News Aggregation in the World
📰 Aktx News

Aktx News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Aktx. Real-time updates on events, politics, business and more.

Akari Therapeutics (NASDAQ:AKTX) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a report published on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Price Performance AKTX opened at $1.36 on Thursday. The stock’s 50 day moving average price is $1.69 and its 200-day moving average price is […]
Exchange Commission Omnia Family Wealth Akari Therapeutics Plc Zakari Therapeutics Free Report Family Wealth
Source: wkrb13.com

Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research report report published on Tuesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Performance AKTX stock opened at $1.17 on Tuesday. Akari Therapeutics has a 1 year low of $1.08 and a 1 […]
Omnia Family Wealth Sabby Management Akari Therapeutics Plc Renaissance Technologies Cerity Partners Zakari Therapeutics
Source: wkrb13.com

Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Large Growth in Short Interest

Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) was the target of a large increase in short interest during the month of March. As of March 31st, there was short interest totalling 10,500 shares, an increase of 75.0% from the March 15th total of 6,000 shares. Approximately 0.2% of the shares of the stock are […]
Sabby Management Omnia Family Wealth Akari Therapeutics Company Profile Cerity Partners Renaissance Technologies Akari Therapeutics Plc

Akari Therapeutics (NASDAQ:AKTX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a report issued on Saturday. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Trading Up 4.4 % Shares of NASDAQ AKTX opened at $1.89 on Friday. Akari Therapeutics has a 1 year low of $1.66 and a […]
Akari Therapeutics Plc Omnia Family Wealth Sabby Management Renaissance Technologies Cerity Partners Zakari Therapeutics
Source: wkrb13.com

Akari Therapeutics, Plc (NASDAQ:AKTX) Sees Significant Drop in Short Interest

Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) saw a large decline in short interest in January. As of January 31st, there was short interest totalling 1,900 shares, a decline of 66.7% from the January 15th total of 5,700 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average […]
Cerity Partners Renaissance Technologies Sabby Management Akari Therapeutics Company Profile Akari Therapeutics Plc Omnia Family Wealth

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Akari Therapeutics (NASDAQ:AKTX) Receives New Coverage from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Get Free Report) in a report released on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock. Akari Therapeutics Trading Down 13.6 % NASDAQ:AKTX opened at $2.60 on Friday. The company’s 50 day moving average price is $3.01 and […]
Renaissance Technologies Cerity Partners Sabby Management Akari Therapeutics Company Profile Akari Therapeutics Plc Zakari Therapeutics

Short Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Drops By 50.0%

Akari Therapeutics, Plc (NASDAQ:AKTX – Get Free Report) saw a large decrease in short interest in December. As of December 15th, there was short interest totalling 1,700 shares, a decrease of 50.0% from the November 30th total of 3,400 shares. Based on an average daily volume of 12,000 shares, the days-to-cover ratio is currently 0.1 […]
Cerity Partners Renaissance Technologies Sabby Management Akari Therapeutics Plc Zakari Therapeutics Get Free Report

Akari Therapeutics (NASDAQ:AKTX) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research note released on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Price Performance Shares of Akari Therapeutics stock opened at $2.96 on Monday. The stock has a 50-day moving average price of $3.26 and […]
Renaissance Technologies Sabby Management Cerity Partners Akari Therapeutics Plc Zakari Therapeutics Free Report
Source: wkrb13.com

Akari Therapeutics (NASDAQ:AKTX) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research note issued to investors on Monday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Trading Up 1.4 % Shares of NASDAQ:AKTX opened at $2.84 on Monday. Akari Therapeutics has a 1 year low of […]
Sabby Management Cerity Partners Akari Therapeutics Plc Renaissance Technologies Zakari Therapeutics Free Report

Akari Therapeutics (NASDAQ:AKTX) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research note released on Friday. The firm issued a sell rating on the biopharmaceutical company’s stock. Akari Therapeutics Stock Performance Shares of AKTX stock opened at $2.91 on Friday. The firm has a fifty day simple moving average of $3.51 and […]
Akari Therapeutics Plc Renaissance Technologies Akari Therapeutics Company Profile Cerity Partners Sabby Management Zakari Therapeutics

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science